At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 504 enrolled
Drug / intervention
SHR0302 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Randomized, Double-blind, Placebo-controlled Adaptive Seamless Phase 2/3 Clinical Study to Evaluate the Efficacy and Safety of SHR0302 in Active Ankylosing Spondylitis Subjects
In Brief
A Phase 3 clinical trial evaluating SHR0302 and SHR0302 placebo for Ankylosing Spondylitis. Completed, enrolled 504 participants across 1 site.
Detailed Summary
This study is to evaluate the efficacy and safety of different doses of JAK1 inhibitor SHR0302 in subjects with active ankylosing spondylitis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAnkylosing Spondylitis
CountriesChina
Collaborators--
Timeline
Phase 3CompletedFinished
202120222023202420252026
First PostedJul 2020
Enrollment StartOct 2020
Primary CompletionNov 2022
Study CompletionMay 2023
TodayJul 2026
First PostedJul 22, 2020
Enrollment StartOct 14, 2020
Primary CompletionNov 15, 2022
Study CompletionMay 12, 2023
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 5.9 years ago
Interventions
SHR0302drug
SHR0302, oral, once daily
SHR0302 placebodrug
SHR0302 placebo, oral, once daily